Literature DB >> 3081830

Function of dopamine receptors in Parkinson's disease: prolactin responses.

A Laihinen, U K Rinne.   

Abstract

In 64 patients with Parkinson's disease (PD), the basal level of prolactin (PRL) was normal. Bromocriptine (BCT) caused a significant suppression of PRL in all parkinsonian patients and controls. When given after BCT treatment, thyrotropin-releasing hormone (TRH) induced a significantly lower PRL rise in recent-onset parkinsonian patients than in controls or advanced patients. In advanced parkinsonian patients with daily fluctuations in disability, the corresponding TRH-induced PRL response was significantly higher than in controls. In advanced parkinsonian patients without fluctuations, the PRL response to TRH was almost the same as in controls.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081830     DOI: 10.1212/wnl.36.3.393

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen.

Authors:  S Brené; N Lindefors; M Herrera-Marschitz; H Persson
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

Review 2.  The hypothalamus in Parkinson disease.

Authors:  R Sandyk; R P Iacono; C R Bamford
Journal:  Ital J Neurol Sci       Date:  1987-06

3.  Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson's disease.

Authors:  Jacob S Daniel; Jyothish P Govindan; Chandan Kamath; Charles D'Souza; Mohamed A Adlan; Lakdasa D Premawardhana
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2014-05-01

4.  The synergistic effect of minocycline and azole antifungal drugs against Scedosporium and Lomentospora species.

Authors:  Fang Yang; Yi Sun; Qiaoyun Lu
Journal:  BMC Microbiol       Date:  2022-01-12       Impact factor: 3.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.